|
RU2746362C1
|
|
Combined drug with antiviral effect against new sars-cov-2 coronavirus
|
|
RU2733361C1
|
|
Agent for inhibition of replication of sars-cov-2 virus mediated by rna interference
|
|
RU2700788C1
|
|
Method for assessment of efficiency of allergen-specific immunotherapy in allergic rhinitis
|
|
RU2710895C1
|
|
Composition inhibiting expression of interleukin-4 and interleukin-13 genes for therapy of allergic rhinitis
|
|
RU2694576C2
|
|
Immunogenic composition containing synthetic peptides repeating sequence of v3-loop of shell protein gp120 hiv1
|
|
RU2650755C1
|
|
Method for cleaning the medicament of prolonged action on the basis of the recombinant analogue of alpha-17 interferon for viral hepatitis c treatment
|
|
RU2661088C1
|
|
Method for purification of sustained-release drug based on recombinant interferon beta-1b analogue for the treatment of multiple sclerosis
|
|
RU2641091C1
|
|
Application of fullerene c60 aqueous solution as therapeutic agent at atopic dermatitis disease
|
|
RU2641041C1
|
|
Composition for atopic dermatitis therapy based on fulleren
|
|
RU2656140C2
|
|
Method for obtaining a hybrid protein containing a fused protein analogue of an interferon gamma conjugated with oligosaccharide
|
|
RU2639388C1
|
|
Composition for viral hepatitis c therapy
|
|
RU2614124C1
|
|
Optimized gene encoding recombinant ipfiii protein
|
